Supernus Pharmaceuticals | SUPN - Gross Profit On Sales


Supernus Pharmaceuticals reported $129.36M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Abbott USD 6.65B 787M Jun/2026
ANI Pharmaceuticals USD 124.18M 12.39M Dec/2025
Aurora Cannabis CAD 29.79M 16.83M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Canopy Growth CAD 8.26M 13.2M Mar/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Corcept Therapeutics USD 162.02M 37.56M Mar/2026
Eisai JPY 153.41B 15.44B Mar/2026
Eli Lilly USD 15.92B 1.33B Dec/2025
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Pacira USD 126.64M 15.61M Mar/2026
Perrigo USD 325.5M 36.7M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Supernus Pharmaceuticals USD 129.36M 34.68M Mar/2026
United Therapeutics USD 315.5M 286.6M Dec/2025
Xeris Pharmaceuticals USD 72.55M 404K Mar/2026